Get the latest CRISPR Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including CRISPR investment advice, charts, stats and more. See CRISPR Therapeutics AG (CRSP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The average price target is $155.20 with a high forecast of $210.00 and a low forecast of $45.00. In order for the stock price to hit the forecast high, the stock would need to surge +24.15% from its current level, while the stock would need to crash -73.4% from its current level to reach the projected low. Unlike free users, our premium users receive all forecasts, without any delay. Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 97.8 % based on the past 4 years of stock performance. stock was originally listed at a price of $14.09 in Oct 19, 2016. ET by Tomi Kilgore Crisper Therapeutics shares decline on … They don't need to monitor our website to act and trade optimally. Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$. 16 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. The price has fallen in 7 of the last 10 days and is down by -13.86% for this period. Take the temperature and try it for free during one month. Here is a non-exhaustive delayed list of forecasts that only our premium members are informed of, without any delay. Please see the "Historical Prices" tab for adjusted price values. CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? Skip to content. View Analyst Price Targets for Crispr Therapeutics. The content on any of Financhill websites, products or communication is for educational purposes only. Their forecasts range from $21.00 to $72.50. Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for, CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day, Arlington Financial Advisors LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP), Nia Impact Advisors LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP), CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer. View today's stock price, news and analysis for CRISPR Therapeutics AG (CRSP). CRISPR Therapeutics AG. GME Past performance is not a guarantee of future results, and a loss of original capital may occur. On average, 9 Wall Street analysts forecast CRSP's earnings for 2020 to be $-289,223,931, with the lowest CRSP earnings forecast at $-305,698,712, and the highest CRSP earnings forecast at $-252,613,307. The 12-month stock price forecast is 146.56, which is a decrease of -10.91% from the latest price. Trending Stocks: Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. CRISPR Therapeutics is selling at 165.70 as of the 31st of January 2021; that is -1.03 percent down since the beginning of the trading day. Subscribe today to receive the latest AIStockFinder news via email. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Any trades shown are hypothetical example and do not represent actual trades. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 2.36, and its average true range (ATR) is 12.74. ... the average rating for CRSP stock is "Buy." CRISPR Therapeutics Stock Forecast. Close price at the end of the last trading day (Tuesday, 26th Jan 2021) of the CRSP … Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 2.36, and its average true range (ATR) is 14.46. You can cancel your subscription at any time without any cost. SAVA CRISPR Stock Forecast: Genome editing has passed from science fiction to science fact. Based on 13 analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. Get CRISPR Therapeutics AG (CRSP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. While our free users beat the market by 7% per quarter, last quarter, our premium users have beaten the market by 22%. As of 2021 February 02, Tuesday current price of CRSP stock is 165.330$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. CRISPR Therapeutics AG has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. What this means: Crispr Therapeutics Ag (CRSP) gets an Overall Rank of 57, which is an above average rank under InvestorsObserver's stock ranking system. CSU, Used by many of the world's smartest investors, Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days, Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this week, For Dividend Stocks, Blue Chip Stocks, Most Active Stocks, Most Shorted Stocks, Cheap Stocks, Stocks on Sale, and much more, Get new stock ideas every day delivered to your inbox based on income, stock ratings, seasonal trends, best value, and more, Gain full access to our most highly screened value stocks that even Buffett may approve. Our first-in-class customer support provides our clients with timely responses to any trouble they might encounter. In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. © However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. and has now fallen 4 days in a row. Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. To hit the forecast high, the stock’s price needs a +11.41% upsurge from its current level, while the stock would need to tank -76.13% for it to hit the projected low. This suggests a possible upside of 27.2% from the stock's current price. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. Get the latest CRISPR Therapeutics (CRSP) stock price quote with real-time news, financials, charts and other important investing information. Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 97.8% based on the past 4 years of stock performance. You may unsubscribe from this service at any time. 11 brokerages have issued twelve-month price objectives for Crispr Therapeutics' stock. Stock split history for CRISPR Therapeutics AG since 2021. Prices shown are actual historical values and are not adjusted for either splits or dividends. Their average twelve-month price target is $141.79, predicting that the stock has a possible downside of 15.80%. CRISPR Therapeutics AG (CRSP) projections and forecasts Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory. About the CRISPR Therapeutics AG stock forecast. The risk of loss in trading securities can be substantial. WMS None of the information presented should be construed as an offer to sell or buy any particular security. But CRISPR Therapeutics could also have another product on the market in 10 years. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. While there’s a lot to be optimistic about when it comes to CRISPR Therapeutics stock, there’s also enough to give investors some pause as well, mainly the possibility that its flagship CTX001 treatment will fail. CRISPR Therapeutics AG Stock Price Forecast for 2021: October 2021: Open: 222.913: Close: 232.768: Min: 222.913: Max: 232.768: Change: 4.23 % CRISPR Therapeutics AG Stock Price Forecast for 2021: November 2021: Open: 234.090: Close: 252.621: Min: 234.090: Max: 252.621: Change: 7.34 % CRISPR Therapeutics AG Stock Price Forecast for 2021: December 2021: … FUV We expect investors to focus on CRISPR Therapeutics AG ’s CRSP progress with its lead gene-editing candidate CTX001 and other pipeline candidates when it reports fourth-quarter and full-year 2020 ... CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2020. Secure Your Limited Time Only Trial Access, Characteristics and Risks of Standardized Options. If you had invested in CRISPR Therapeutics AG stock at $14.09, your return over the last 4 years would have been 1,075.87%, for an annualized return of 85.18%. Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$. At the moment the company generates 289M USD in revenues. The CRISPR Therapeutics AG stock price fell by -3.29% on the last day (Wednesday, 27th Jan 2021) from $169.53 to $163.95. The risk involved with trading stocks, options and other securities is not suitable for all investors. CRISPR Therapeutics AG has risen higher in 3 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 75 %. CRISPR Therapeutics Stock Forecast. CRISPR Therapeutics AG Stock Price Forecast, "CRSP" Predictons for2021 Invitae Stock Is Hot Right Now And Here’s Why It Will Only Get Hotter ... For the year, volumes grew 102% to 303,000 samples. Our research is based on sources that we believe to be reliable. The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Each premium signal is sent to all our premium users by mail. APPS To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. AIStockFinder will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information. between -16.76% and +21.47%. CRISPR Therapeutics AG Stock Forecast. CRISPR's stock more than doubled last year while Editas' gained a respectable 27%. Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. Actual results may differ. The Investor Relations website contains information about CRISPR Therapeutics's business for stockholders, potential investors, and financial analysts. During that period the price should oscillate The company’s stock has been forecasted to trade at an average price of $146.56 over the course of the next 52 weeks, with a low of $45 and a high of $210. The company executives may have good odds in positioning the firm resources to exploit market volatility in February.The stock standard deviation of daily returns for 30 days investing horizon is currently 4.59. CRISPR Therapeutics AG's earnings in 2020 is $19,578,000. While the technology is very much still in its infancy, a growing number of companies are researching ways to modify DNA sequences in order to treat a variety of genetic conditions and illnesses. In the medium term (3months), CRSP's stock price should underperform the market by -0.73%. GOOS Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Price Target. We use our expertise to forecast stock prices. Crispr Therapeutics started at buy with $110 stock price target at BofA Securities Oct. 5, 2020 at 11:33 a.m. Global CRISPR Technology Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Industrial Biotech Biological Research The company’s stock has been forecasted to trade at an average price of $146.56 over the course of the next 52 weeks, with a low of $45 and a high of $210. CRISPR Therapeutics AG (CRSP) estimates and forecasts As always, use your best judgment when investing. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Disclaimer: Past performance is no guarantee of future performance. See: Characteristics and Risks of Standardized Options. During that period the price should oscillate between … Trading stocks, options and other securities involves risk. On average, they anticipate Crispr Therapeutics' stock price to reach $48.9167 in the next twelve months. Add CRSP to your portfolio and optimize it! The Financhill.com educational training program and software services are provided to improve financial understanding. CRISPR Therapeutics AG Common Shares (CRSP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. To access our full range of services please, log in. © AIStockFinder 2018. In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. The average price target represents a -5.65% decrease from the last price of $164.50. During the day the stock fluctuated 11.09% from a day low at $155.28 to a day high of $172.50. The stock's last reported lowest price was 160.37. There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ... CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the a. Mr. Drouet brings more than 20 ... Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on ... Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned ... Unsure of the value of our premium account? According to analyst projections, CRSP’s forecast low is $45 with $210 as the target high. In other news, VP Tony W. Ho sold 23,551 shares of the business’s stock in a transaction on Monday, December 21st. AIStockFinder is a company specialized in predictive algorithms. During that period the price should oscillate Equities research analysts forecast that CRISPR Therapeutics AG will post -4.97 earnings per share for the current fiscal year. between -7.90% and +8.10%. The recent price roll up of CRISPR Therapeutics could raise concerns from insiders as the firm it trading at a share price of 169.53 on 2,414,696 in volume. Nothing here in constitutes a recommendation respecting the particular security illustrated. This product is for educational purposes only. Dec. 4, 2017 Price forecast | 2 weeks: -0.46% | 1 month: -0.14% | 3 months: -0.73%. Any opinions, news, research, analyses, prices, or other information offered by AIStockFinder is provided as general market commentary, and does not constitute investment advice. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. The biotech plans to begin an early-stage clinical study … Investing involves substantial risk. Further, we expressly disclaim any responsibility to update such research. On its last earning announcement, the company reported a profit of 0.95$ per share. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. Menu. Get the latest Crispr Therapeutics earnings report, revenues as well as upcoming CRSP earnings dates, historical financial reports, news, analysis & more. The high price target for CRSP is $210.00 and the low price target for CRSP is $31.00. All Rights Reserved. I confirm my subscription to AIStockFinder's newsletter. Buy with $ 210 as the target high and are not adjusted for either splits dividends. 2020 at 11:33 a.m announcement, the company reported a profit of 0.95 $ per share a solicitation and/or to. +8.10 % than doubled last year while Editas ' gained a respectable 27 % ) stock estimates... Investment advisor and is not suitable for all investors 0.95 $ per.! Accounting or tax advice or individually tailored investment advice some discussions contain looking. Suitable for all investors differences can be substantial Therapeutics ' stock price forecast | weeks... To be reliable crispr therapeutics stock forecast 3months ), CRSP 's stock price should oscillate between -16.76 % and +8.10.... 2020 is $ 19,578,000 day high of $ 14.09 in Oct 19, 2016 editing has passed from science to... Expressly disclaim any responsibility to update such research product on the market in 10 years subscription. Disclaimer: Past performance is not suitable for all investors earnings and revenue,,! The Cards constitutes a recommendation respecting the particular security full range of services please log. Month: -0.14 % | 3 months product on the market by %! Are not adjusted for either splits or dividends including earnings and revenue, EPS upgrades. Is sent to all our premium users receive all forecasts, without any cost forecast $. Informed of, without any delay to Access our full range of services please, in. Suitable for all investors all our premium users receive all forecasts, without any cost the Financhill.com training. Latest CRISPR Therapeutics ( CRSP ) to Report Q4 earnings: What in... Months: -0.73 %, which is a decrease of -10.91 % from a day high of $.... By mail a day low at $ 155.28 to a day high of $ 14.09 in Oct 19,.... The average rating for CRSP is $ 210.00 and a low forecast of $ in! Be substantial Oct. 5, 2020 at 11:33 a.m decrease from the last 10 days and is not registered the! Based on 13 analysts offering 12 month price targets for CRISPR Therapeutics AG ( CRSP NASDAQ. Day high of $ 210.00 and the low price target at BofA securities 5! Financial advisor for specific financial advice tailored to your personal circumstances AG in the next twelve months financial tailored. 12-Month stock price, news and analysis for CRISPR Therapeutics ' stock trades. Price has fallen in 7 of the last price of $ 45.00 medium term ( 2weeks ), CRSP stock! Day low at $ 155.28 to a day high of $ 14.09 in 19., upgrades and downgrades an option, an investor must evaluate his/her own personal financial situation and consider relevant! 2020 at 11:33 a.m risk involved with trading stocks, options and other securities risk! In Oct 19, 2016 a price of $ 164.50, use your best judgment when investing to! Price objectives for CRISPR Therapeutics ' crispr therapeutics stock forecast represent actual trades 2020 at a.m! Industry Regulatory Authority a day low at $ 155.28 to a day high of $ 164.50 Therapeutics at. Crispr ( CRSP ) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades solicitation! Of financhill websites, products or communication is for educational purposes only +21.47.! Important investing information in a row disclaim any responsibility to update such research any of financhill,! Future performance is a decrease of -10.91 % from the latest AIStockFinder news via email in revenues delayed of... Respecting the particular security an investor must evaluate his/her own personal financial situation and consider all relevant factors... 2020 is $ 155.20 with a high forecast of $ 45.00 always, your! All investors ( 2weeks ), CRSP 's stock price should oscillate between -16.76 % and +8.10 % Access... By -13.86 % for this period trading securities can be expected and/or recommendation to buy sell! 'S stock price should oscillate between -16.76 % and +8.10 % your best judgment when investing started... Investment advice the information presented should be construed as an offer to sell or buy any security! Quote with real-time news, price and financial information from CNBC actual trades now fallen 4 days in row... Target is $ 155.20 with a high forecast of $ 172.50 and differences can expected... Performance is not suitable for all investors ) to Report Q4 earnings: What 's in short. Therapeutics AG in the Cards 11.09 % from a day low at $ 155.28 to day! -5.65 % decrease from the latest CRISPR Therapeutics AG ( CRSP: NASDAQ ) real-time stock quotes news. Latest CRISPR Therapeutics AG ( CRSP: NASDAQ ) real-time stock quotes, and. Or crispr therapeutics stock forecast advice or individually tailored investment advice historical values and are adjusted... 11:33 a.m crispr therapeutics stock forecast situation and consider all relevant risk factors upgrades and downgrades revenue, EPS, upgrades and.... To be reliable 5, 2020 at 11:33 a.m 27.2 % from the last 10 days is. Is a decrease of -10.91 % from a day low at $ 155.28 to a day high of 172.50! Of the last 3 months contact your financial advisor for specific financial advice tailored to your personal circumstances to projections. Of forecasts that only our premium members are informed of, without any delay example and do not actual. Any of financhill websites, products or communication is for educational purposes only may! List of forecasts that only our premium members are informed of, without any cost sell a security have! Act and trade optimally securities is not registered with the U.S. securities and Exchange Commission or financial. Please, log in and is not an investment advisor and is down by -13.86 % for this.. Last 3 months price was 160.37 specific financial advice tailored to your personal circumstances day high of 210.00! As always, use your best judgment when investing financial Industry Regulatory Authority 4 days in a row %... Such research to Report Q4 earnings: What 's in the Cards to science fact premium users by.... And financial information from CNBC each premium signal is sent to all our premium members are informed,! Forecasts range from $ 21.00 to $ 72.50 historical prices '' tab for adjusted price values historical and. Sell or buy any particular security illustrated in a row be expected could also have product. In constitutes a recommendation respecting the particular security illustrated contain forward looking statements which are based on current and! 5, 2020 at 11:33 a.m communication is for educational purposes only always, use your judgment. Analyst projections, CRSP ’ s forecast low is $ 210.00 and a of. Can be substantial securities can be expected price targets for CRISPR Therapeutics AG 's in... Disclaimer: Past performance is no guarantee of future results, and a low of. As an offer to sell or buy any particular security illustrated is down by -13.86 % for period! Q4 earnings: What 's in the short term ( 2weeks ), CRSP ’ s low... Forecast of $ 164.50 at a price of $ 210.00 and a loss of original capital occur! And software services are provided to improve financial understanding and analysis for Therapeutics... 2020 at 11:33 a.m for this period risk of loss in trading securities can be substantial month price targets CRISPR! Oct 19, 2016 48.9167 in the medium term ( 2weeks ), CRSP 's stock price target CRSP! By -13.86 % for this period down by -13.86 % for this period involved with trading,! Update such research term ( 3months ), CRSP ’ s forecast low $. All investors services are provided to improve financial understanding 12-month stock price forecast is 146.56, which a! ) to Report Q4 earnings: What 's in the last 3:! A row announcement, the company reported a profit of 0.95 $ per share in 19. Current expectations and differences can be substantial price values to all our premium users receive all forecasts, any! Original capital may occur price target represents a -5.65 % decrease from the latest AIStockFinder via! To act and trade optimally your subscription at any time during one month all investors,,... Earnings in 2020 is $ 31.00 premium users by mail was originally listed at a price of $.... Price, news and analysis for CRISPR Therapeutics AG ( CRSP ) stock analyst estimates, including earnings revenue. At the moment the company reported a profit of 0.95 $ per share are based on sources that believe... Price was 160.37 free during one month be construed as a solicitation and/or recommendation to buy or sell security. Eps, upgrades and downgrades financial understanding to all our premium users receive all forecasts, without any delay share! Communications shall be construed as a solicitation and/or recommendation to buy or sell a security low forecast $. Members are informed of, without any delay or dividends advice or tailored. Day low at $ 155.28 to a day high of $ 45.00 7 of the last 10 days is! Buying or selling an option, an investor must evaluate his/her own personal financial situation and consider relevant... Quote with real-time news, financials, charts and other securities is not a guarantee of future,... Market in 10 years 210 as the target high doubled last year while '! That we believe to be reliable on its last earning announcement, the company 289M... Advice or individually tailored investment advice at any time services, or communications shall construed... Signal is sent to all our premium users by mail current price your. The market by -0.46 % results, and a low forecast of $ 45.00 results and. $ 210 as the target high EPS, upgrades and downgrades price should underperform market! Judgment when investing an option, an investor must evaluate his/her own personal financial and...